In clinical research, most attention naturally flows toward drugs, targets, and biological mechanisms. We debate molecules, pathways, and patient populations. Yet one of the most decisive elements of any clinical trial is often barely visible outside the methods section.

It is the definition of the endpoint.

An endpoint is not simply a variable collected in a database. It is a formal statement of what “success” means in a clinical study. And small, technical-looking choices in how endpoints are defined can quietly shift the fate of a development program, sometimes as strongly as the drug itself.

The Illusion of Objectivity

At first glance, endpoints appear objective. A tumor progresses. A patient dies. A hospitalization occurs.

But behind each of these outcomes lies a long chain of methodological decisions.

Should progression be assessed by local investigators or by an independent central review?
Should deaths without documented progression be counted as events or censored?
How strict should imaging windows be, and what happens if scans are late?
How should missing assessments be handled, and should informative missingness be assumed?

What is the exact rule for event time when assessments occur at discrete visits?

Each of these decisions shapes the observed event times, the censoring mechanism, and the statistical model that follows. They also shape potential bias pathways: who is more likely to be called a progressor, whose event is captured earlier, and whose data becomes censored.

Two trials can evaluate the same drug in the same population and obtain meaningfully different results simply because their endpoints were constructed differently.

How Definitions Create Effects

Endpoint definitions influence much more than the label of a variable. They affect the number and timing of events, the amount and pattern of censoring, the shape of survival curves, the estimated treatment effect, and the probability of crossing a regulatory significance threshold.

Some definitions favor early separation of curves, for example by using tighter windows or more aggressive event rules. Others emphasize long-term durability, for example by requiring confirmatory progression, allowing treatment beyond progression, or using endpoints that incorporate sustained response. Some choices increase statistical power by capturing more events. Others increase uncertainty by increasing censoring or creating competing risks that blur interpretation.

In this sense, endpoint definitions do not merely measure treatment effects. They partially create them by deciding what counts as an event, when it happens, and which patients meaningfully contribute information.

The Endpoint Estimand Connection

Modern guidance has increasingly emphasized estimands, meaning the precise question the trial aims to answer, including how to handle intercurrent events such as treatment discontinuation, new therapy, rescue medication, death, or missed visits.

This matters because endpoints are often treated as obvious, while the scientific question is not.

Are we estimating the effect regardless of what happens after discontinuation, which aligns with a treatment policy strategy?
Or the effect if patients adhered and no rescue therapy occurred, which aligns with a hypothetical strategy?
Or the effect up to the start of new therapy, which aligns with a while on treatment strategy?

These are different scientific questions. The endpoint definition is where the question becomes operational, and where ambiguity can creep in unnoticed.

A Regulatory and Ethical Responsibility

Because of this, endpoint definitions carry a responsibility that is both scientific and ethical. They determine when a patient is considered to have failed treatment, which patients are counted as responders, whether a trial is declared positive or negative, and whether a drug advances to the next phase or is abandoned.

These are not abstract statistical consequences. They shape patient access, development decisions, and sometimes the future of entire therapeutic areas.

There is also an ethical dimension in how endpoints distribute credit and failure. Definitions that censor heavily can unintentionally down weight patients with poorer follow-up or more fragile health, exactly the patients a treatment may need to help. Conversely, definitions that treat ambiguous outcomes as failures can penalize patients with irregular assessment schedules. Endpoint rules can amplify inequities if they align with systematic differences in monitoring, access, or adherence.

Bringing Endpoints into the Foreground

It is encouraging that regulatory discussions increasingly emphasize clear endpoint construction, pre specification, and sensitivity analyses that probe alternative assumptions. But culturally, endpoint definitions still tend to remain hidden in technical appendices, treated as a procedural detail rather than a core design choice.

Perhaps it is time to change that.

In many clinical trials, the most influential design decision is not the dose, the comparator, or even the sample size.

It is the definition.

Because long before the first patient is dosed, and long before the first p value is calculated, the endpoint has already decided how reality will be interpreted, what is counted, what is ignored, and what is considered true enough to call success.

And in biostatistics, interpretation is often everything.

Manuel Pfister